Charles River Laboratories International (NYSE:CRL – Free Report) had its target price reduced by Wells Fargo & Company from $280.00 to $275.00 in a research report released on Friday morning, Marketbeat Ratings reports. They currently have an overweight rating on the medical research company’s stock. A number of other equities research analysts have also recently […]
Charles River Laboratories International (NYSE:CRL – Free Report) had its price objective reduced by Guggenheim from $255.00 to $225.00 in a research note published on Friday morning, MarketBeat reports. They currently have a buy rating on the medical research company’s stock. A number of other equities research analysts have also recently weighed in on CRL. […]
Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) was the target of a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 1,540,000 shares, an increase of 11.6% from the August 15th total of 1,380,000 shares. Based on an average daily volume of […]
Tilia Fiduciary Partners Inc. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 17.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,750 shares of the medical research company’s stock after purchasing an additional 837 shares during […]
Confluence Investment Management LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) in the 2nd quarter, Holdings Channel reports. The fund acquired 84,001 shares of the medical research company’s stock, valued at approximately $17,661,000. Several other institutional investors and hedge funds have also made changes to their positions in […]